Compare Campbell Soup Co. (CPB) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Quest Diagnostics Inc — how do they compare? Campbell Soup Co. trades at $22.6 (market cap $6.78B), while Quest Diagnostics Inc trades at $237.43 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 3.9× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | DGX | |
|---|---|---|
Market Cap | $6.78B | $26.21B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $238.50 |
52-Week Low | $20.00 | $173.49 |
Enterprise Value | $13.38B | $31.97B |
Dividend Yield | 6.87% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.56, up 0.6% with bullish technical signals and mixed fundamentals. The stock shows strong valuation metrics with P/E of 11.1 and P/S of 0.7, while recent earnings beat expectations in Q1 2026. Revenue growth remains modest at $10.3B in 2025, though net margins compressed to 5.9%. Technical indicators suggest bullish momentum with support at $22 and resistance at $23.
CPB offers a compelling 7% dividend yield supported by stable cash flows, but faces margin pressure and analyst skepticism with only 3% buy ratings. The company's cost-saving initiatives and new product launches provide potential upside, though competitive pressures and consumer spending trends remain key risks for sustained growth.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
